2024-03-29T02:33:02Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00022265
2022-12-15T03:52:35Z
453:456
471:537:538:1198
微量アスピリン・チクロピヂン併用・患者別コントロールによる抗血小板療法の研究 : 第二報 脳梗塞再発防止についての中間報告
微量アスピリン・チクロピヂン併用・患者別コントロールによる抗血小板療法の研究 : 第二報 脳梗塞再発防止についての中間報告
Studies on Antiplatelet Therapy by Combination of Low-dose Aspirin and Ticlopidine, and by Control of Individual Patients. 2nd Report. Preliminary Report on Secondary Prevention of Cerebral Infarction.
服部, 晃
布施, 一郎
帯刀, 亘
柴田, 昭
伊藤, 粋子
渡部, 透
真田, えい
小田, 勇司
滝沢, 慎一郎
矢沢, 光良
本間, 義章
飯泉, 俊雄
栗林, 和敏
antiplatelet therapy
cerebral infarction
aspirin
ticlopidine
抗血小板療法
脳梗塞
アスピリン
チクロピヂン
We have studied antiplatelet therapy by low-dose aspirin combined with ticlopidine under the control of platelet aggregation individually for secondary prevention of cerebral infarction (CI) and a preliminary results were reported. Eighty six patients (9 with TIA, 2 with RIND or 75 with CI) were treated by our protocol (Niigata Med. J. 101;642, 1987) for an average of 22 months. The doses of drugs were for aspirin at 10-75 (median 30) mg/day and for ticlopidine at 50-300 (median 200) mg/day. Cerebrovascular reattacks in all and recurrence of CI were 3.18% and 2.08% (patient x year), respectively. Mild non-fatal bleeding occurred in 4 patients. None of patients died during this study. In conclusion our method is turned out, at least, as effective as those reported by others, and seems safe in clinical application.
新潟医学会
1990-05
jpn
departmental bulletin paper
http://hdl.handle.net/10191/34073
https://niigata-u.repo.nii.ac.jp/records/22265
AN00182415
00290440
新潟医学会雑誌
新潟医学会雑誌
104
5
381
386
https://niigata-u.repo.nii.ac.jp/record/22265/files/104(5)_381-386.pdf
application/pdf
1.4 MB
2019-08-16